在中国的推动下,STAR外科2025年的Q4销售量逐年增长18.1%,但没有达到预期值,导致在兼并延迟和全球销售量下降的情况下股本下降11.2%。 STAAR Surgical's Q4 2025 sales rose 18.1% year-over-year, driven by China, but missed expectations, causing an 11.2% stock drop amid merger delays and global sales decline.

STAAR外科医生报告说,2025年Q4净销售额为5 780万美元,比上一年增加18.1%,原因是中国销售额增加,尽管经销商因停止与Alcon公司合并而调整了存货。 STAAR Surgical reported Q4 2025 net sales of $57.8 million, up 18.1% year-over-year, driven by stronger China sales despite inventory corrections from distributor adjustments linked to its halted merger with Alcon. 该公司的净损失较小,每股0.37美元,总利润率提高至75.7%,并指定了临时共同首席执行干事。 The company posted a narrower net loss of $0.37 per share, improved gross margin to 75.7%, and named interim co-CEOs. 虽然中国的销售额回升至1 750万美元,但全球在中国以外的净销售额下降,公司未达到预期收入,导致股票下跌11.2%。 While China sales rebounded to $17.5 million, global net sales outside China declined, and the company missed revenue expectations, leading to an 11.2% stock drop. 管理层对2026年仍保持谨慎乐观。 Management remains cautiously optimistic for 2026.